CTD²: Cancer Target Discovery and Development

The Cancer Target Discovery and Development (CTD2) Network, a functional genomics initiative, bridges the gap between cancer genomics and biology. The Network aims to understand how tumor heterogeneity leads to drug resistance in order to develop optimal combinations of chemotherapy or small molecules in combination with immunotherapy. 

Banner for CTD squared program. Links to CTD squared program page
Last updated: January 03, 2019

News & Publications

previousnext
Scheme summarizing the molecular network driving the intrinsic GPX4 dependency and ferroptosis susceptibility in clear-cell carcinomas
CTD²
April 08, 2019

Clear-cell carcinomas (CCCs) are a histological group of highly aggressive malignancies commonly originating in the kidney and ovary. CCCs are distinguished by aberrant lipid and glycogen accumulation and are refractory to a broad range of anti-cancer therapies. Here we identify an intrinsic...

Ras-Driven Cancer
CTD²
March 22, 2019
Ovarian Tumor Microenvironment
CTD²
March 21, 2019

We hypothesized that candidate dependencies for which there are small molecules that are either approved or in advanced development for a non-oncology indication may represent potential therapeutic targets. To test this hypothesis, we performed genome-scale loss-of-function screens in hundreds...

CTD²
March 18, 2019

Protein kinase C (PKC) isozymes function as tumor suppressors in increasing contexts. In contrast to oncogenic kinases, whose function is acutely regulated by transient phosphorylation, PKC is constitutively phosphorylated following biosynthesis to yield a stable, autoinhibited enzyme that is...

AKT mediated Cell growth scheme
CTD²
March 15, 2019

Despite the important role of the PI3K/AKT/mTOR axis in the pathogenesis of cancer, to date there have been few functional oncogenic fusions identified involving the AKT genes. A 12-year-old female with a histopathologically indeterminate epithelioid neoplasm was found to harbor a novel fusion...

O
O
O
O
O